Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
24 11 2019
Historique:
received: 27 10 2019
revised: 18 11 2019
accepted: 22 11 2019
entrez: 28 11 2019
pubmed: 28 11 2019
medline: 10 9 2020
Statut: epublish

Résumé

Portal sinusoidal vascular disease is a presinusoidal cause of portal hypertension (PHT) of unknown etiology, characterized by typical manifestations of PHT (esophageal varices, ascites, portosystemic collaterals), plaquetopenia and splenomegaly with a gradient of portal pressure slightly increased, according to the presinusoidal nature of the PHT. A few cases in the literature have shown a relationship between oxaliplatin and the development of presinusoidal portal hypertension, years after the chemotherapy for colorectal cancer (therefore, different to sinusoidal obstruction syndrome). There are three mechanisms through which oxaliplatin can cause sinusoidal damage: 1) damage at the level of endothelial cells and stimulates the release of free radicals and depletion of glutathione transferase, with altering the integrity of the sinusoidal cells. The damage in the endothelial sinusoidal cells allows to erythrocytes to across into the Dissé space and formation of perisinusoidal fibrosis, 2) the appearance of nodular regenerative hyperplasia is favored by the chronic hypoxia of the centrilobular areas and, finally, 3) oxaliplatin can generate an obliteration of the blood capillaries and zones of parenchymal extinction. These three facts can develop, in a minority of cases, the appearance of a presinusoidal increase of portal pressure, which typically appears years after the completion of chemotherapy and sometimes is underdiagnosed until variceal bleeding, ascites or encephalopathy appear. The knowledge of this pathology is essential to be able to perform an early diagnostic and consult to the hepatologist

Identifiants

pubmed: 31771307
pii: cells8121506
doi: 10.3390/cells8121506
pmc: PMC6952805
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Oxaliplatin 04ZR38536J

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Am J Med. 1976 Oct;61(4):459-64
pubmed: 1086057
Gastroenterol Hepatol. 2017 Oct;40(8):538-580
pubmed: 28610817
Clin Colorectal Cancer. 2012 Sep;11(3):224-7
pubmed: 22537609
Dig Dis Sci. 2011 Jan;56(1):227-35
pubmed: 20499175
Hepatology. 2010 Jan;51(1):210-8
pubmed: 19821530
Int J Exp Pathol. 1993 Apr;74(2):211-7
pubmed: 8499322
N Engl J Med. 2004 Jun 3;350(23):2343-51
pubmed: 15175436
Liver Transpl. 2018 Feb;24(2):171-181
pubmed: 29156507
J Clin Oncol. 2010 May 20;28(15):2549-55
pubmed: 20406923
Hepatology. 1990 May;11(5):787-97
pubmed: 2189821
J Clin Oncol. 2006 May 1;24(13):2065-72
pubmed: 16648507
Ann Surg Oncol. 2011 Mar;18(3):659-69
pubmed: 20976564
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
Am J Gastroenterol. 2013 Jun;108(6):926-32
pubmed: 23419380
Am J Gastroenterol. 2009 Jul;104(7):1707-14
pubmed: 19471257
Gut. 2002 Aug;51(2):275-80
pubmed: 12117894
Ann Oncol. 2004 Mar;15(3):460-6
pubmed: 14998849
Hepatology. 2019 Dec;70(6):2228-2230
pubmed: 31318454
Hepatology. 2016 Jul;64(1):224-31
pubmed: 26990687
Crit Rev Oncol Hematol. 2002 Jun;42(3):317-25
pubmed: 12050023
J Hepatol. 2013 Aug;59(2):318-26
pubmed: 23624001
Lancet Gastroenterol Hepatol. 2019 May;4(5):399-411
pubmed: 30957754
Hepatology. 2016 Jun;63(6):1977-86
pubmed: 26874653
Gastroenterol Clin Biol. 2006 Nov;30(11):1313-6
pubmed: 17185976
Hepatology. 2018 Dec;68(6):2413-2423
pubmed: 30066417
Dig Liver Dis. 2019 Sep;51(9):1348-1350
pubmed: 31320304
Hepatology. 2011 Sep 2;54(3):1071-81
pubmed: 21574171
Dig Liver Dis. 2012 Oct;44(10):855-60
pubmed: 22721839
Hepatol Int. 2017 Sep;11(5):452-460
pubmed: 28597108
J Hepatol. 2016 Jan;64(1):179-202
pubmed: 26516032
Clin Colorectal Cancer. 2009 Oct;8(4):225-30
pubmed: 19822514
Surgery. 2009 Apr;145(4):362-71
pubmed: 19303984
J Natl Cancer Inst. 2018 Aug 1;110(8):888-894
pubmed: 29346573
Hepatology. 2014 Jun;59(6):2276-85
pubmed: 24155091
Gastroenterology. 2010 Oct;139(4):1238-45
pubmed: 20547163
Cardiovasc Intervent Radiol. 1999 Jul-Aug;22(4):311-4
pubmed: 10415221
PLoS One. 2011;6(7):e21478
pubmed: 21779329
Histopathology. 2010 Mar;56(4):430-9
pubmed: 20459550
Intern Med. 2015;54(4):383-7
pubmed: 25748953
J Cancer. 2019 Apr 25;10(8):1923-1929
pubmed: 31205551
J Hepatol. 2017 Aug;67(2):399-411
pubmed: 28223101
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908
Toxics. 2015 Jun 05;3(2):198-223
pubmed: 29056658
Br J Radiol. 2015 Feb;88(1046):20140653
pubmed: 25514699
Hepatol Int. 2007 Sep;1(3):398-413
pubmed: 19669336

Auteurs

Angela Puente (A)

Digestive Disease Department, Marqués de Valdecilla University Hospital, Cantabria University, Av. Valdecilla s/n, 39008 Santander, Spain.
Health Research Institute Marques de Valdeciila, IDIVAL, 39011 Santander, Spain.

Jose Ignacio Fortea (JI)

Digestive Disease Department, Marqués de Valdecilla University Hospital, Cantabria University, Av. Valdecilla s/n, 39008 Santander, Spain.
Health Research Institute Marques de Valdeciila, IDIVAL, 39011 Santander, Spain.

Carmen Del Pozo (C)

Digestive Disease Department, Marqués de Valdecilla University Hospital, Cantabria University, Av. Valdecilla s/n, 39008 Santander, Spain.
Health Research Institute Marques de Valdeciila, IDIVAL, 39011 Santander, Spain.

Patricia Huelin (P)

Digestive Disease Department, Marqués de Valdecilla University Hospital, Cantabria University, Av. Valdecilla s/n, 39008 Santander, Spain.
Health Research Institute Marques de Valdeciila, IDIVAL, 39011 Santander, Spain.

Maria Luisa Cagigal (ML)

Pathology department, Marqués de Valdecilla University Hospital, 39011 Santander, Spain.

Marina Serrano (M)

Oncology Department, Marques de Valdecilla, University Hospital, IDIVAL, 39011 Santander, Spain.

Joaquin Cabezas (J)

Digestive Disease Department, Marqués de Valdecilla University Hospital, Cantabria University, Av. Valdecilla s/n, 39008 Santander, Spain.
Health Research Institute Marques de Valdeciila, IDIVAL, 39011 Santander, Spain.

Maria Teresa Arias Loste (MT)

Digestive Disease Department, Marqués de Valdecilla University Hospital, Cantabria University, Av. Valdecilla s/n, 39008 Santander, Spain.
Health Research Institute Marques de Valdeciila, IDIVAL, 39011 Santander, Spain.

Paula Iruzubieta (P)

Digestive Disease Department, Marqués de Valdecilla University Hospital, Cantabria University, Av. Valdecilla s/n, 39008 Santander, Spain.
Health Research Institute Marques de Valdeciila, IDIVAL, 39011 Santander, Spain.

Antonio Cuadrado (A)

Digestive Disease Department, Marqués de Valdecilla University Hospital, Cantabria University, Av. Valdecilla s/n, 39008 Santander, Spain.
Health Research Institute Marques de Valdeciila, IDIVAL, 39011 Santander, Spain.

Susana Llerena (S)

Digestive Disease Department, Marqués de Valdecilla University Hospital, Cantabria University, Av. Valdecilla s/n, 39008 Santander, Spain.
Health Research Institute Marques de Valdeciila, IDIVAL, 39011 Santander, Spain.

Carlos Lopez (C)

Oncology Department, Marques de Valdecilla, University Hospital, IDIVAL, 39011 Santander, Spain.

Emilio Fábrega (E)

Digestive Disease Department, Marqués de Valdecilla University Hospital, Cantabria University, Av. Valdecilla s/n, 39008 Santander, Spain.
Health Research Institute Marques de Valdeciila, IDIVAL, 39011 Santander, Spain.

Javier Crespo (J)

Digestive Disease Department, Marqués de Valdecilla University Hospital, Cantabria University, Av. Valdecilla s/n, 39008 Santander, Spain.
Health Research Institute Marques de Valdeciila, IDIVAL, 39011 Santander, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH